Dr.ย Takayukiย Yoshino
MD, PhD
Deputy Director & Director, Department of Gastrointestinal Oncology
corporate_fareNational Cancer Center Hospital East, Kashiwa, Japan
Takayuki Yoshino
MD, PhD
Dr. Takayuki Yoshino is Deputy Director of the National Cancer Center Hospital East (NCCHE) in Kashiwa, Japan, and Director of its Department of Gastrointestinal Oncology. He is one of Asia's foremost authorities in colorectal cancer, internationally recognised for his leadership in precision oncology, biomarker-driven therapy, and clinical trial development.
With nearly 30 years of oncology experience, Dr. Yoshino trained at the National Defense Medical College and subsequently at the National Cancer Center Research Institute, Shizuoka Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, and Vanderbilt-Ingram Cancer Center. Since returning to NCCHE in 2007, he has led the department through multiple landmark milestones in colorectal cancer research. He has been a principal investigator or steering committee member on trials including BEACON CRC, FRESCO-2, PARADIGM, and major HER2-positive and MSI-H colorectal cancer studies. He has authored more than 300 peer-reviewed publications in journals such as The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, and Annals of Oncology. Beyond clinical research, Dr. Yoshino chairs the Pan-Asian Adapted ESMO Guidelines for Colorectal Cancer, serves as Vice President of the Japanese Society of Clinical Oncology (JSCO), and is a member of the ASCO Breakthrough Advisory Committee.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Yoshino at the National Cancer Center Hospital East, subject to institutional availability and case acceptance.
Why Consider Dr. Takayuki Yoshino?
Dr. Yoshino combines nearly three decades of clinical leadership in gastrointestinal oncology with an unmatched track record in international colorectal cancer trials and global guideline development, making him a leading choice for patients with complex CRC and GI malignancies in Asia.
Areas of Specialisation
Colorectal cancer, gastrointestinal oncology, precision medicine, and biomarker-driven therapy
Dr. Yoshino's practice spans the full spectrum of gastrointestinal oncology, with a primary focus on colorectal and metastatic colorectal cancer. His specialisation integrates molecular profiling, biomarker testing, and evidence-based clinical trial approaches to optimise treatment for each patient.
Colorectal Cancer โ Precision Oncology
Biomarker-guided systemic therapy for metastatic and advanced colorectal cancer, including RAS/KRAS, BRAF, HER2, and MSI-H subgroups.
- arrow_rightAnti-EGFR therapy selection based on RAS and KRAS mutation status
- arrow_rightMolecularly stratified first- and second-line regimen planning
- arrow_rightBiomarker testing integration into systemic treatment decisions
- arrow_rightHER2-targeted treatment for eligible mCRC patients
- arrow_rightClinical trial evaluation for HER2-directed novel agents
- arrow_rightBEACON CRC-based combination BRAF/MEK/EGFR inhibitor approaches
- arrow_rightBiomarker-driven selection for BRAF V600E-mutated disease
- arrow_rightImmune checkpoint inhibitor therapy for MSI-H metastatic colorectal cancer
- arrow_rightMSI testing and immunotherapy eligibility assessment
- arrow_rightCombination immunotherapy approaches in selected patients
Gastrointestinal Oncology โ Broader GI Cancers
Clinical and translational expertise across gastric, oesophageal, and advanced digestive system malignancies.
- arrow_rightSystemic chemotherapy and targeted therapy for advanced gastric cancer
- arrow_rightMultimodality treatment planning in collaboration with surgical teams
- arrow_rightEvaluation for innovative clinical trial programmes at NCCHE
- arrow_rightAccess to FRESCO-2 and related refractory mCRC trial designs
Drug Development & Translational Research
Investigator-led development of novel agents and biomarker strategies for gastrointestinal malignancies.
- arrow_rightPrincipal investigator on international cooperative group trials
- arrow_rightSteering committee roles in ESMO-aligned GI oncology programmes
- arrow_rightTranslational research linking molecular profiles to treatment outcomes
- arrow_rightInternational advisory roles on predictive biomarker programmes
Procedures & Clinical Services
Systemic therapy, precision oncology, clinical trials, and expert second opinions
Dr. Yoshino's clinical services at NCCHE encompass biomarker-guided systemic therapy, targeted treatment, immunotherapy, clinical trial access, and expert second opinions for patients with colorectal and other gastrointestinal cancers.
Systemic Chemotherapy for GI Cancers
Medical OncologyComprehensive first- and subsequent-line chemotherapy planning for metastatic colorectal, gastric, and other gastrointestinal cancers.
Anti-EGFR & Targeted Therapy
Targeted TherapyMolecularly guided targeted therapy selection based on RAS, KRAS, BRAF, and HER2 biomarker profiling.
Immunotherapy for MSI-H CRC
Medical OncologyCheckpoint inhibitor therapy and immunotherapy planning for patients with microsatellite instability-high colorectal cancer.
Clinical Trial Evaluation
Complex DiseaseAssessment for enrolment in innovative clinical trials at NCCHE, including international cooperative studies in colorectal and GI oncology.
Expert Second Opinion
Second OpinionIndependent expert review of complex colorectal and gastrointestinal cancer cases, including biomarker interpretation, treatment sequencing, and trial eligibility.
Multidisciplinary Cancer Care
MultidisciplinaryCoordinated treatment planning across medical oncology, surgical oncology, radiology, pathology, and supportive care for GI cancer patients.
Research & Publications
Over 300 peer-reviewed publications in leading international journals
Dr. Yoshino is among the most prolific gastrointestinal oncology researchers in Asia, with more than 300 peer-reviewed publications in The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Annals of Oncology. His research spans precision oncology, biomarker development, immunotherapy, and international clinical trial design for colorectal and GI cancers.
Dr. Yoshino's full publication list is available on PubMed and through the National Cancer Center Japan. A detailed research summary can be provided on request through CancerFax.
Education & Training
Dr. Yoshino completed his medical training at the National Defense Medical College in Japan, followed by residency, specialist pathology and gastrointestinal oncology training at the National Cancer Center, and international fellowships at leading US cancer centres.
Clinical Experience
Dr. Yoshino has held progressively senior roles at the National Cancer Center Hospital East since 1999, rising to his current position as Deputy Director and Department Director for Gastrointestinal Oncology. A period at Shizuoka Cancer Center and international training in the United States broadened his clinical and research expertise before he returned to NCCHE in 2007.
Languages & International
Dr. Yoshino consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting in languages beyond those listed, including Korean and Chinese.
CancerFax can coordinate professional medical interpreter support for additional languages when required.
How CancerFax Helps You Access Dr. Takayuki Yoshino
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Takayuki Yoshino's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Takayuki Yoshino's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Takayuki Yoshino before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Takayuki Yoshino's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Takayuki Yoshino's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Takayuki Yoshino's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Takayuki Yoshino
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Yoshino at the National Cancer Center Hospital East in Japan, subject to institutional availability and case acceptance. Please submit your medical reports through CancerFax to begin the process.
Dr. Yoshino specialises in colorectal cancer and gastrointestinal oncology. He has particular expertise in metastatic colorectal cancer, including RAS/KRAS wild-type, BRAF-mutated, HER2-positive, and MSI-H subtypes. He also treats gastric cancer, oesophageal cancer, and other advanced gastrointestinal malignancies.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the National Cancer Center Hospital East, subject to availability and case suitability.
Yes. A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging, and treatment history. Dr. Yoshino's team is particularly well placed to review complex colorectal cancer cases involving biomarker selection, treatment sequencing, or clinical trial eligibility. Consultation format and availability are subject to institutional protocols.
Yes. Dr. Yoshino has been a principal investigator or steering committee member on landmark international trials including BEACON CRC, FRESCO-2, and the PARADIGM trial. The National Cancer Center Hospital East continues to run investigational programmes for colorectal and other gastrointestinal cancers. Eligibility for specific trials depends on individual patient criteria and current study availability.
Biomarker-guided treatment uses molecular testing โ such as RAS, KRAS, BRAF, HER2, and MSI status โ to identify which therapies are most likely to work for a specific patient's tumour. Dr. Yoshino is internationally recognised for advancing this approach in colorectal cancer, helping patients avoid therapies unlikely to benefit them and guiding selection of targeted or immunotherapy options where appropriate.
Connect with Takayuki Yoshino Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.